Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2020-03-10 Proxy Solicitation & In…
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
关于召开2020年第二次临时股东大会的提示性公告
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed announcement about the convening of the 2020 second extraordinary general meeting (临时股东大会) of Shenzhen BGI Genomics Co., Ltd. It includes information about the meeting date, voting procedures (both onsite and online), agenda items to be discussed and voted on, registration details, and attachments such as proxy forms and voting instructions. There is no financial data or results reported, nor is it a transcript or presentation. It is not a report publication announcement since it contains substantive details about the meeting itself rather than just announcing a report release. The document is clearly an official notice related to a shareholders' meeting, specifically a notice to convene and provide details for the meeting. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or Proxy Solicitation & Information Statement (PSI). However, since this document is about the notice and instructions for the meeting and voting, not the results or solicitation materials, it aligns best with Proxy Solicitation & Information Statement (PSI).
2020-03-10 Chinese
关于受让高林厚健（上海）创业投资合伙企业（有限合伙）财产份额暨关联交易的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shenzhen BGI Genomics Co., Ltd. regarding the progress of acquiring a property share in an investment fund (Gao Lin Hou Jian (Shanghai) Venture Capital Partnership) and related party transactions. It details the transaction overview, signing of the transfer agreement, changes in limited partners, and completion of industrial and commercial registration changes. The document includes references to previous announcements and legal documents but does not contain financial statements or detailed financial performance data. It is a regulatory announcement about a capital investment transaction and related updates, not a financial report or earnings release. The document length is about 4706 characters, which is substantial but the content is clearly an update on capital investment and related party transaction progress. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2020-03-03 Chinese
关于全资子公司产品取得欧盟自由销售证书的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (1260 characters) from Shenzhen BGI Co., Ltd. about its wholly-owned subsidiary obtaining a Free Sales Certificate from the Danish Medicines Agency for a COVID-19 nucleic acid test kit. It describes the certificate details, product market situation, and potential impact on the company. There are no financial statements, no detailed financial data, no regulatory certifications, or voting results. The document is an announcement of a regulatory or product approval event, not a financial report or management discussion. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a legal proceeding or M&A activity. It is a regulatory announcement about product certification and market access. Given the content and length, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2020-03-01 Chinese
2019年度业绩快报
Earnings Release Classification · 95% confidence The document is titled '2019 年度业绩快报' which translates to '2019 Annual Performance Express Report' or '2019 Annual Earnings Quick Report'. It contains preliminary financial data for the year 2019, including revenue, profit, net income, and other financial metrics. The text explicitly states that the data is preliminary and unaudited, and that the final audited data will be disclosed in the 2019 Annual Report. The document is relatively short (2615 characters) and serves as an initial earnings announcement with key financial highlights rather than a full annual report. This matches the definition of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. It is not a full Annual Report (10-K), nor an Audit Report (AR), nor a Report Publication Announcement (RPA) because it contains substantive financial data and analysis, not just a notice of report availability. Therefore, the correct classification is Earnings Release (ER). FY 2019
2020-02-28 Chinese
独立董事关于第二届董事会第十七次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on matters discussed at the 17th meeting of the second board of directors of Shenzhen BGI Genomics Co., Ltd. It discusses opinions on related party transactions, guarantees provided to subsidiaries, and guarantees accepted from related parties for the year 2020. The content focuses on governance and compliance with regulations and company articles, reflecting the independent directors' assessment and approval of these matters to be submitted to the shareholders' meeting. There is no financial data, earnings information, or detailed report content. The document is a governance-related statement by independent directors rather than a full report or announcement of financial results. Therefore, it fits best under Board/Management Information (MANG), which covers announcements related to board or management matters, including independent directors' opinions on board meeting resolutions.
2020-02-26 Chinese
关于2020年度公司及子公司接受关联方担保的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from Shenzhen Huada Gene Co., Ltd. regarding the company's and its subsidiaries' acceptance of related party guarantees for the year 2020. It includes extensive information about the related party transactions, the financial status of the guaranteed entities, the relationship between the parties, the decision-making process, and opinions from the board, independent directors, and supervisory board. The document is not a financial report like an annual or interim report, nor is it a call transcript or earnings release. It is a regulatory announcement about a related party transaction involving guarantees, which is a typical regulatory filing to comply with stock exchange rules. The document is lengthy (9549 characters) and contains substantive content about the transaction, not just a brief notice or a report publication announcement. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such detailed regulatory announcements that do not fit other specific categories.
2020-02-26 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.